Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 109 от 222

Набира участници Фаза 3

The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

Intracerebral Hemorrhage Spontaneous Intracerebral Hemorrhage Supratentorial Intracerebral Haemorrhage Acute Intracerebral Haemorrhage +1

This is a domain within the ACT-GLOBAL platform trial to compare the effectiveness of early and appropriate pharmacological interventions in acute intracerebral hemorrhage (ICH) to control secondary brain injury. Up to 2000 patients with presumed spontaneous supratentorial intracerebral hemorrhage (ICH) will be followed for 6 months (or death, if prior to 6 months). Adaptive interim analyses will be used, with statistical triggers to determine if any of the interventions are superior to control. The end of the trial is defined as the date that all participants have completed their 6-month assessment. A large amount of preclinical data indicates that the outcome from ICH is linked to the detrimental effects of breakdown substances from brain bleeds. However, there remains a lack of compelling evidence supporting the effectiveness of any pharmacological intervention that can mitigate the secondary cerebral injury. The INTERACT domain aims to assess the effectiveness of intravenous deferoxamine and low-dose oral colchicine, both individually and in combination, to standard of care alone, on improving functional outcome in patients with spontaneous supratentorial ICH. Those patients who meet eligibility criteria will be randomized to receive one of four interventions: 1. No deferoxamine mesylate and no colchicine (labeled as control) 2. Deferoxamine mesylate only: deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) post-randomization and continue for the following 2 consecutive days. 3. Colchicine only: 0.5mg of oral colchicine daily for 30 consecutive days. 4. Both deferoxamine mesylate and colchicine: deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) post-randomization and continue for the following 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days.

Начало: 27.02.2025 Край: 01.01.2028 Възраст: 18–80 г. Лечение

Australia, China The George Institute NCT06763055

Набира участници Фаза 2/3

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Prostate Cancer

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment

Начало: 27.02.2025 Край: 19.07.2033 Възраст: 18–100 г. Лечение

Australia, Brazil, China +8 Novartis Pharmaceuticals NCT06780670

Набира участници Фаза 3

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Gastric Cancer Gastroesophageal Junction Cancer

This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy and safety of T-DXd plus a fluoropyrimidine versus SoC chemotherapy plus trastuzumab in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS \

Начало: 27.02.2025 Край: 01.02.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +21 Daiichi Sankyo NCT06731478

Набира участници

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

Cancer of Breast Trastuzumab Emtansine Trastuzumab Deruxtecan

Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea

Начало: 26.02.2025 Край: 30.09.2029 Възраст: от 19 г.

South Korea Seoul National University Hospital NCT06928818

Набира участници Фаза 1

A Study of HS-20110 in Participants With Advanced Solid Tumors

Solid Tumors

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors

Начало: 26.02.2025 Край: 30.09.2027 Възраст: от 18 г.

China, United States Hansoh BioMedical R&D Company NCT06892379

Набира участници Фаза 3

Reducing Breathlessness With Dronabinol in COPD Patients

COPD Breathlessness Cannabis

This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).

Начало: 26.02.2025 Край: 01.10.2026 Възраст: от 18 г.

Denmark Vejle Hospital NCT06473701

Набира участници

Identifying Patterns in the Breath of Individuals With Breast Cancer

Breast Cancer

Researchers will compare the breath profiles of women with breast cancer and those without to determine whether there are disease-specific patterns that can be leveraged to facilitate breast cancer detection. Women with mammogram-confirmed breast tissue density undergoing standard-of-care breast cancer screening will be invited to participate. Those who provide informed consent will provide one breath sample and fill out a questionnaire about their medical history with help from the research coordinators. Breath samples will be collected prior to standard of care biopsy or MRI, and patients will be stratified into the case or control group based on their test results. The primary goal of this project is to use exhaled alveolar breath and the subsequent spectral data produced by Breathe BioMedical's cavity ring-down spectrometer to further develop Breathe BioMedical's technology and machine learning algorithms to determine the feasibility of detecting breast cancer in women aged 40 to 74. Secondarily, this project aims to identify patterns of VOCs that are either over- or under-represented in participants with breast cancer when compared to the breath profiles of participants without breast cancer. This project will also assess performance characteristics of the technology (e.g. sensitivity, specificity, false negative rate, and false positive rate) including subgroup analyses. This project aims to understand intra-subject variability by exploring differences in breath signatures before and after definitive management of breast cancer, including surgical resection.

Начало: 25.02.2025 Край: 01.12.2027 Възраст: 40–74 г.

United States Breathe BioMedical Inc NCT06512350

Набира участници Фаза 1

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or trametinib in participants with advanced solid tumors.

Начало: 25.02.2025 Край: 01.08.2027 Възраст: от 18 г. Лечение

Australia, United States Vividion Therapeutics, Inc. NCT06804824

Набира участници Фаза 3

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Extensive-Stage Small Cell Lung Cancer

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.

Начало: 25.02.2025 Край: 05.09.2031 Възраст: от 18 г. Лечение

Argentina, Australia, Austria +23 Bristol-Myers Squibb NCT06646276

Набира участници Ранна Фаза 1

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients

Atherosclerotic Cardiovascular Disease Acute Coronary Syndromes

The goal of this clinical trial is to learn if UDP-003 is safe in healthy human participants and patients, assess the pharmacokinetics (PK)/pharmacodynamics (PD) of UDP-003 in healthy human participants and patients and its potential efficacy in patients. Researchers will compare UDP-003 to a placebo in a blinded manner. This first in human, randomised, double-blind, placebo-controlled, prospective, single-centre trial with a modular dose-finding design will be conducted in 3 parts: * Part 1: 6 cohorts of 6 healthy participants receiving Single Ascending Doses (SADs), * Part 2: 3 cohorts of 12 healthy participants receiving Multiple Ascending Doses (MADs) (6 doses over 16 days), * Part 3: 1 cohort of 12 participants diagnosed with acute coronary syndrome (ACS; non-ST elevation myocardial infarction \[NSTEMI\] or unstable angina) at least 12 months post-event receiving multiple doses (6 administrations of the 25 mg/kg dose over 16 days). The planned duration of the study for each participant will be: * 4 weeks for SAD Participants (1-day treatment period, 4-week safety follow-up) * 6 weeks for MAD Participants (16-day treatment period,4-week safety follow-up) * 28 weeks for MD Patients (6-week treatment period, 6-month safety follow-up) Prior to participants being randomised to panels of increasing doses, all safety data will be reviewed for completed panels.

Начало: 25.02.2025 Край: 30.06.2027 Възраст: 18–79 г. Лечение

Australia Cyclarity Therapeutics, Inc. NCT06813339

Набира участници Фаза 3

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Sjögren's Syndrome

The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.

Начало: 25.02.2025 Край: 11.12.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Amgen NCT06747949

Набира участници

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

Alzheimer's Disease

The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.

Начало: 24.02.2025 Край: 30.09.2029 Възраст: от 19 г.

United States Eisai Korea Inc. NCT06810960

Набира участници Фаза 3

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Non-small Cell Lung Cancer

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell Lung Cancer.

Начало: 24.02.2025 Край: 01.12.2028 Възраст: от 18 г.

China Sichuan Baili Pharmaceutical Co., Ltd. NCT06838273

Набира участници Фаза 1

A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors

Solid Cancer

This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.

Начало: 24.02.2025 Край: 30.08.2028 Възраст: 18–75 г. Лечение

Australia Akeso NCT06730386

Набира участници Фаза 1/2

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Japanese Encephalitis Virus Disease

This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)

Начало: 24.02.2025 Край: 19.03.2028 Възраст: от 18 г. Превенция

Australia, New Zealand SK Bioscience Co., Ltd. NCT06680128

Набира участници

Capstan Medical TMVR Study: FIH

Mitral Regurgitation

This study is a prospective, multi-center, non-randomized first in human study to evaluate the safety and feasibility of the Capstan Medical TMVR System for intervention in adults with moderate-severe or greater mitral regurgitation who are not surgical candidates.

Начало: 24.02.2025 Край: 01.12.2030 Възраст: от 18 г. Устройства

Australia, Chile, New Zealand Capstan Medical NCT06600191

Набира участници Фаза 1/2

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.

Начало: 24.02.2025 Край: 01.01.2028 Възраст: от 18 г. Лечение

Australia, China CStone Pharmaceuticals NCT06741644

Набира участници

Diagnostic Performance of a Combination of Leukocyte Cell Surface Markers in Predicting the Risk of Severe Bacterial Infection in Febrile Children Under Three Months of Age in the Emergency Department: a Pilot Study.

Children Under 3 Months of Age With Fever

Fever is a frequent reason for emergency department (ED) visits in infants under 3 months of age. Although viral infections are the most common etiologies, the prevalence of severe bacterial infections (SBI) is high (10%). While in infants with SBI, establishing the diagnosis and initiating rapid intravenous antibiotic therapy is necessary, every effort should be made to avoid it in those at low risk of SBI. Clinical examination and biomarkers are still sub-optimal for assessing the risk of SBI. As a result, the vast majority of these children receive inpatient intravenous antibiotic therapy. Flow cytometry is a technique for measuring the expression of biomarkers on the cell surface of leukocytes in response to infection. A French team has identified a combination of some fifteen leukocyte cell surface markers that perform excellently in discriminating between bacterial and viral infections in a population of adults presenting to the emergency department with a suspected infection. However, there are no similar studies in children. The objective of the study is to assess the diagnostic performance of a combination of biomarkers on the cell surface of leukocytes in discriminating between bacterial and viral infection. Infants less than 3 months of age, visiting the ED for fever will have an extra blood sample in order to measure those biomarkers. The performance of those biomarkers to identify SBI will be assessed.

Начало: 24.02.2025 Край: 07.09.2027 Възраст: 7–90 г.

France Assistance Publique - Hôpitaux de Paris NCT06618989

Набира участници

The Efficacy of Transcutaneous Pulsed Radiofrequency Acupuncture for Knee Osteoarthritis

Osteoarthritis (OA) of the Knee

Efficacy of transcutaneous acupoint pulsed radiofrequency with rehabilitation for knee osteoarthritis.

Начало: 24.02.2025 Край: 30.06.2028 Възраст: 45–85 г.

Taiwan Shin Kong Wu Ho-Su Memorial Hospital NCT06702046

Набира участници

Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device

Breast Cancer, Metastatic Breast Cancer Invasive Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up

Начало: 24.02.2025 Край: 30.11.2026 Възраст: от 18 г.

France ScreenCell NCT06807502

1 … 107 108 109 110 111 … 222